USPTO serial 99550037
REYSTORDYS
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- GLUECK, CHRISTOPHER N
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with REYSTORDYS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $349*
Plus Government fees of $150
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Rockville, MD, US
Rockville, MD, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
William R. Samuels
William R. Samuels Cole-Frieman & Mallon, LLP201 California street, Suite 350San Francisco, CA 94111United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biological preparations for medical use in the treatment of genetic diseases and disorders, and muscle disorders, namely, Duchenne muscular dystrophy; Pharmaceutical preparations, namely, recombinant adeno-associated viral (rAAV) vectors for use in gene therapy; Pharmaceutical preparations for the treatment of genetic diseases and disorders, and muscle disorders, namely, Duchenne muscular dystrophy; Clinical medical reagents for use in gene therapy; Therapeutic pharmaceutical compositions that include recombinant adeno-associated viral (rAAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy; Pharmaceutical preparations containing adeno-associated viral (AAV) vectors and nucleic acids for a system delivering genes to biological cells for use in the treatment of genetic diseases and disorders, namely, Duchenne muscular dystrophy; Gene therapy preparation for medical use containing genetic materials for sustained protein expression, namely, microdystrophin expression | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 14, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 19, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 19, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 13, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 20, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 20, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 16, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 16, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 16, 2025 | NWAP | NEW APPLICATION ENTERED | — |